An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
Public ClinicalTrials.gov record NCT05492877. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of Mitiperstat (AZD4831), for 12-24 Weeks, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Study identification
- NCT ID
- NCT05492877
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 381 participants
Conditions and interventions
Conditions
Interventions
- Mitiperstat (AZD4831) Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 13, 2022
- Primary completion
- Aug 11, 2024
- Completion
- Aug 11, 2024
- Last update posted
- Aug 28, 2025
2022 – 2024
United States locations
- U.S. sites
- 19
- U.S. states
- 11
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Newport Beach | California | 92663 | — |
| Research Site | Clearwater | Florida | 33765 | — |
| Research Site | DeLand | Florida | 32720 | — |
| Research Site | Miami | Florida | 33186 | — |
| Research Site | Orlando | Florida | 32825 | — |
| Research Site | Tampa | Florida | 33606 | — |
| Research Site | Winter Park | Florida | 32789 | — |
| Research Site | Chicago Ridge | Illinois | 60415 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Chesterfield | Missouri | 63017 | — |
| Research Site | Saint Charles | Missouri | 63301 | — |
| Research Site | New Windsor | New York | 12553 | — |
| Research Site | Gastonia | North Carolina | 28054 | — |
| Research Site | Kernersville | North Carolina | 27284 | — |
| Research Site | New Bern | North Carolina | 28562 | — |
| Research Site | Columbus | Ohio | 43215 | — |
| Research Site | Choctaw | Oklahoma | 73020 | — |
| Research Site | Fort Mill | South Carolina | 29707 | — |
| Research Site | Amarillo | Texas | 79106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05492877, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05492877 live on ClinicalTrials.gov.